newsfilter
← Latest News
GlobeNewswire·

Adhera Therapeutics Signs Exclusive License Agreement with Melior Pharmaceuticals I for New Type 1 Diabetes Drug Candidate

Adhera to develop MLR-1023 as a new drug for Type I diabetes with a focus on C-peptide positive patients (~320,000 – 480,000 patients in U.S.) Laboratory and clinical research support MLR-1023 as the world's first safe, effective beta cell proliferat